Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Skull Base Surgery|January 1, 1995
Skull base tumor volume and surgical margins: a pilot studyC Schwimmer, J Weissman, A M Simon, et al.
Nucleic Acids Research|March 10, 2001
Inactivation of Saccharomyces cerevisiae OGG1 DNA repair gene leads to an increased frequency of mitochondrial mutantsK K Singh, B Sigala, H A Sikder, et al.
The Laryngoscope|January 22, 2002
Gastroesophageal reflux and obstructive sleep apneaB A Senior, M Khan, C Schwimmer, et al.
Analytical Biochemistry|February 1, 1996
Fluorometric titration of the mitochondrial ADP/ATP carrier protein in muscle homogenate with atractyloside derivativesP Roux, A Le Saux, C Fiore, et al.
Biochemistry|December 17, 1996
Conformational changes of the yeast mitochondrial adenosine diphosphate/adenosine triphosphate carrier studied through its intrinsic fluorescence. 1. Tryptophanyl residues of the carrier can be mutated without impairing protein activityA Le Saux, P Roux, V Trézéguet, et al.
Biochemistry|December 17, 1996
Conformational changes of the yeast mitochondrial adenosine diphosphate/adenosine triphosphate carrier studied through its intrinsic fluorescence. 2. Assignment of tryptophanyl residues of the carrier to the responses to specific ligandsP Roux, A Le Saux, V Trézéguet, et al.
Protein Expression and Purification|June 2, 2000
Purification of histidine-tagged mitochondrial ADP/ATP carrier: influence of the conformational states of the C-terminal regionC Fiore, V Trézéguet, P Roux, et al.
Biochimie|May 20, 1998
The mitochondrial ADP/ATP carrier: structural, physiological and pathological aspectsC Fiore, V Trézéguet, A Le Saux, et al.
HIV Medicine|September 19, 2019
Determinants of blood telomere length in antiretroviral treatment-naïve HIV-positive participants enrolled in the NEAT 001/ANRS 143 clinical trialB Alejos, N Stella-Ascariz, R Montejano, et al.
The Journal of Antimicrobial Chemotherapy|December 26, 2015
Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ARTS Lambert-Niclot, E C George, A Pozniak, et al.
Pageof 1